Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;112(5):666-73.
doi: 10.1111/j.1464-410X.2012.11648.x. Epub 2013 Jan 15.

Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort

Chee L Goh  1 , Edward J Saunders, Daniel A Leongamornlert, Malgorzata Tymrakiewicz, Karen Thomas, Elizabeth D Selvadurai, Ruth Woode-Amissah, Tokhir Dadaev, Nadiya Mahmud, Elena Castro, David Olmos, Michelle Guy, Koveela Govindasami, Lynne T O'Brien, Amanda L Hall, Rosemary A Wilkinson, Emma J Sawyer, Ali Amin Al Olama, Douglas F Easton, Zsofia Kote-Jarai, Chris C Parker, Rosalind A Eeles
Affiliations

Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort

Chee L Goh et al. BJU Int. 2013 Sep.

Abstract

Objectives: To explore the potential prognostic role of family history (FH) of prostate cancer and prostate cancer risk single nucleotide polymorphisms (SNPs) in patients undergoing active surveillance (AS) for prostate cancer. This is the first study to date, which has investigated the potential prognostic role of SNP profiles in an AS cohort

Patients and methods: FH data were collected from patients in the Royal Marsden Hospital AS study. In all, 39 prostate cancer-risk SNPs identified from published genome wide association studies (GWAS) were genotyped using the Sequenom Platform and TaqMan™ assays from available DNA. The cumulative genetic-risk scores for each patient were then calculated using the weighted effect estimated from previous GWAS (log-additive model). FH status and the genetic-risk scores were assessed against adverse outcomes in AS, time to treatment and adverse histology on repeat biopsy, using univariable and multivariable Cox regression models to address time to treatment; and binary logistic regression to address biopsy upgrade.

Results: Of 471 patients, 55 (13.6%) had adverse histology on repeat biopsies and 145 (30.8%) had deferred treatment. On univariate analysis, there was no significant relationship between FH of prostate cancer in any degree of relation, and adverse histology or time to treatment. For risk score analyses, 386 patients' DNA was studied; and there was also no relationship found between the calculated genetic risk scores and adverse histology or time to treatment (P = 0.573 and P = 0.965, respectively). The retrospective study design and the few events were the main limitation of the study.

Conclusions: There is currently insufficient data to support the use of FH status or prostate cancer SNP profile risk scores as prognostic factors in AS and these should not be used to influence management decisions. As more genetic variants are discovered this may change and should be reassessed in multicentre AS cohorts.

Keywords: active surveillance; family history; genetic risk profiles; prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risk score distribution generated from SNP genotyping of the AS cohort.
Figure 2
Figure 2
Risk score distributions for patients with or without adverse histology (a) and for patients who did or did not receive active treatment (b).
See this image and copyright information in PMC

References

    1. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85. - PubMed
    1. Goh CL, Schumacher FR, Easton D, et al. Genetic Variants Associated With Predisposition to Prostate Cancer and Potential Clinical Implications. J Intern Med. 2012;271:353–65. - PubMed
    1. Karlsson R, Aly M, Clements M, et al. A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk. Eur Urol. 2012 doi: 10.1016/j.eururo.2012.07.027. [Epub ahead of print] - DOI - PubMed
    1. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. Int J Cancer. 2008;123:430–5. - PubMed
    1. Brandt A, Sundquist J, Hemminki K. Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. Ann Oncol. 2012;23:251–6. - PubMed

Publication types